tiprankstipranks
Structure Therapeutics doses first patients in ACCESS clinical study
The Fly

Structure Therapeutics doses first patients in ACCESS clinical study

Structure Therapeutics (GPCR) announced the first patients have been dosed in the randomized, double-blind, placebo-controlled Phase 2b ACCESS clinical study evaluating GSBR-1290 in participants living with obesity, or overweight with a weight-related comorbidity. GSBR-1290 is an orally-available, nonpeptide small molecule glucagon-like-peptide-1 receptor agonist that has demonstrated competitive weight loss and generally favorable safety and tolerability results in previous studies with once-daily dosing.

Don't Miss our Black Friday Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App